Abstract: The invention relates to a medicament containing an effector of the glutathione metabolism together with ?-lipoic acid for treating diabetes mellitus. This medicament enables disturbances of the thiol-disulfide status or those that occur, for example, in diabetes mellitus to be treated simultaneously, separately or in a temporally graduated manner.
Type:
Grant
Filed:
May 27, 2002
Date of Patent:
September 30, 2008
Assignees:
Esparma GmbH, IMTM GmbH
Inventors:
Michael Taeger, Siegfried Ansorge, Gerhard Fries, Dieter Koegst
Abstract: The present invention relates to the use of at least one effector of glutathione metabolism together with ?-lipoic acid, its salts and/or its pro-drugs for the simultaneous, separate or timed cytoprotective treatment of chronically obstructive lung diseases.
Type:
Application
Filed:
December 23, 2004
Publication date:
September 13, 2007
Applicants:
ESPARMA GMBH, IMTM GMBH
Inventors:
Siegfried Ansorge, Dieter Koegst, Michael Taeger, Gerhard Fries
Abstract: The invention relates to an agent for treating skin diseases and/or functional disorders of the skin on the basis of different medicaments and/or auxiliary substances through promotion of penetration from topical formulations into the skin. According to the invention, the agent is composed of a hyaluronate lyase produced by microbial means and a medicament, preferably a hydrophilic medicament and/or auxiliary substances in different galenic formulations including colloidal carrier systems. The areas of application for the invention in human and veterinary medicament relate to the treatment, prophylaxis and/or metaphylaxis of skin diseases, functional disorders of the skin, the processes of skin ageing and dry skin conditions.
Type:
Grant
Filed:
September 5, 2001
Date of Patent:
April 13, 2004
Assignee:
esparma GmbH
Inventors:
Wolfgang Wohlrab, Reinhard Neubert, Christoph Huschka, Peter-Jürgen Müller, Jörg-Herman Ozegowski, Dieter Koegst, Gerhard Fries
Abstract: The invention relates to an agent for the treatment, prophylaxis and metaphylaxis of functional and structural disorders of the skin caused by external factors. The agent contains a hyaluronic acid partially digested with a microbiological hyaluronate lyase. The hyaluronic acid fragment mixture is incorporated in different galenic formulations to which other hydrophilic and/or lipophilic active substances and/or auxiliary substances can be added. Fields of application of the invention in human and veterinary medicine relate to the treatment and/or the prophylaxis of skin damage caused by environmental factors including UV, dry skin conditions and skin ageing.
Type:
Grant
Filed:
September 10, 2001
Date of Patent:
February 10, 2004
Assignee:
esparma GmbH
Inventors:
Wolfgang Wohlrab, Reinhard Neubert, Christoph Huschka, Peter-Jürgen Müller, Jörg-Herman Ozegowski, Dieter Koegst, Gerhard Fries
Abstract: Lipid metabolic disorders, such as hyperlipidemia or hyperlipoproteinemia can be treated by administering to an afflicted individual an effective amount of 5-(1,2-dithiolan-3-yl) valeric acid (&agr;-lipoic acid) or one of its physiologically acceptable salts. Pharmaceutical compositions containing (&agr;-lipoic acid) and methods for making such compositions also are disclosed.
Type:
Grant
Filed:
October 9, 2001
Date of Patent:
February 11, 2003
Assignees:
BiRD Berolina innovative Research and Development GmbH, esparma GmbH
Inventors:
Rudolf-Giesbert Alken, Dieter Koegst, Gerhard Fries
Abstract: The invention relates to a pharmaceutical preparation in a make-up which is suited for external application and which contains a dithranol derivative as an active ingredient.
Type:
Grant
Filed:
September 17, 2001
Date of Patent:
July 2, 2002
Assignee:
esparma GmbH
Inventors:
Jürgen Schneider, Wolfgang Wohlrab, Reinhard Neubert, Christoph Huschka, Dieter Koegst, Gerhard Fries